Chronic hepatitis B treatment includes nucleoside or nucleotide analogue therapy and pegylated interferon. These therapies suppress hepatitis B virus replication and reduce the risk of cirrhosis and hepatocellular carcinoma. Neither approach eradicates HBV, so hepatocellular carcinoma risk is not eliminated. Nucleoside or nucleotide analogue therapy is taken orally, and entecavir and tenofovir have a low risk of drug resistance. Despite effective viral suppression, these treatments rarely achieve loss of hepatitis B surface antigen, defined as levels below 0.05 IU per milliliter.
"The current treatment of chronic hepatitis B infection includes nucleoside or nucleotide analogue (NA) therapy and pegylated interferon. Both of these treatments are effective in suppressing hepatitis B virus (HBV) replication and in reducing the risk of cirrhosis and hepatocellular carcinoma."
"However, these treatments do not eradicate HBV, and the risk of hepatocellular carcinoma is not eliminated. NA therapy is administered orally, and entecavir and tenofovir are safe with a low risk of drug resistance."
"However, such therapies rarely lead to the loss of hepatitis B surface antigen (HBsAg) (i.e., a level of <0.05 IU per milliliter), which occurs in . . ."
Read at The New England Journal of Medicine
Unable to calculate read time
Collection
[
|
...
]